PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739688
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170810
LR  - 20170810
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Cyclooxygenase-2 Inhibition Enhances Proliferation of NKT Cells Derived from
      Patients with Laryngeal Cancer.
PG  - 4059-4066
AB  - BACKGROUND/AIM: The aim of this study was to analyze whether inhibition of
      cyclooxygenase-2 by celecoxib and the subsequent enhancement in the proliferation
      of natural killer T (NKT) cells could play a role in dendritic cell (DC)-based
      laryngeal cancer (LC) immunotherapy. PATIENTS AND METHODS: Peripheral blood
      mononuclear cells were obtained from 48 male patients diagnosed with LC and 30
      control patients without cancer disease. Neoplastic cell lysate preparations were
      made from cancer tissues obtained after surgery and used for in vitro DCs
      generation. NKT cells proliferation assay was performed based on 3H-thymidine
      incorporation assay. RESULTS: An increased proliferation of NKT cells was
      obtained from control patients compared to NKT cells obtained from LC patients
      regardless of the type of stimulation or treatment. In the patient group
      diagnosed with LC, COX-2 inhibition resulted in a significantly enhanced
      proliferation of NKT cells when stimulated with autologous DCs than NKT cells
      stimulated with DCs without COX-2 inhibition. These correlations were not present
      in the control group. Higher proliferation rate of NKT cells was also observed in
      non-metastatic and highly differentiated LC, which was independent of the type of
      stimulation or treatment. CONCLUSION: COX-2 inhibition could be regarded as
      immunotherapy-enhancing tool in patients with LC.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Klatka, Janusz
AU  - Klatka J
AD  - Department of Otolaryngology and Laryngeal Oncology, Medical University of
      Lublin, Lublin, Poland.
FAU - Grywalska, Ewelina
AU  - Grywalska E
AD  - Department of Clinical Immunology and Immunotherapy, Medical University of
      Lublin, Lublin, Poland.
FAU - Hymos, Anna
AU  - Hymos A
AD  - Department of Otolaryngology and Laryngeal Oncology, Medical University of
      Lublin, Lublin, Poland.
FAU - Guz, Malgorzata
AU  - Guz M
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin,
      Lublin, Poland.
FAU - Polberg, Krzysztof
AU  - Polberg K
AD  - Department of Otolaryngology, MSW Hospital, Lublin, Poland.
FAU - Rolinski, Jacek
AU  - Rolinski J
AD  - Department of Clinical Immunology and Immunotherapy, Medical University of
      Lublin, Lublin, Poland.
FAU - Stepulak, Andrzej
AU  - Stepulak A
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin,
      Lublin, Poland [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Celecoxib/*administration & dosage
MH  - Cell Proliferation/*drug effects
MH  - Cyclooxygenase 2/*genetics
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage
MH  - Dendritic Cells/drug effects/immunology
MH  - Humans
MH  - Immunotherapy
MH  - Laryngeal Neoplasms/*drug therapy/immunology/pathology
MH  - Leukocytes, Mononuclear/drug effects/pathology
MH  - Lymphocyte Activation/drug effects
MH  - Natural Killer T-Cells/drug effects/immunology
OTO - NOTNLM
OT  - NKT cells
OT  - cyclooxygenase-2 inhibitor
OT  - dendritic cells
OT  - proliferation
EDAT- 2017/07/26 06:00
MHDA- 2017/08/11 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/06/02 [received]
PHST- 2017/06/16 [revised]
PHST- 2017/06/19 [accepted]
AID - 37/8/4059 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4059-4066.